Edition:
United States

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

5.51USD
4:00pm EDT
Change (% chg)

$-1.02 (-15.62%)
Prev Close
$6.53
Open
$6.60
Day's High
$6.60
Day's Low
$5.51
Volume
11,027
Avg. Vol
6,153
52-wk High
$11.41
52-wk Low
$4.84

Summary

Name Age Since Current Position

Peter Farrell

75 2018 Chairman of the Board

Joseph Payne

46 2018 President, Chief Executive Officer, Director

Andrew Sassine

52 2018 Interim Chief Financial Officer, Director

Pad Chivukula

2018 Chief Operating Officer, Chief Scientific Officer

Kevin Skol

2018 Senior Vice President - Business Development & Alliance Management

K. Kummerfeld

2018 Vice President - Finance, Corporate Controller

Suezanne Parker

2018 Vice President - Translational Biology

James Barlow

57 2018 Director

Magda Marquet

2018 Director

Biographies

Name Description

Peter Farrell

Dr. Peter Farrell is Chairman of the Board of the Company. Dr. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (NYSE:RMD). Farrell has been Chairman and a director of ResMed since 1989, when the company began as a management buyout of sleep technology from Baxter Healthcare. Peter was previously Foundation Director of the University of New South Wales (UNSW) Graduate School for Biomedical Engineering (1978-89) while simultaneously serving as Vice President of Research & Development for Baxter Healthcare in Tokyo (1984-89). He is also on the board of trustees of The Scripps Research Institute in La Jolla and is Chairman of the Boston-based POC NMR diagnostic company, WaveGuide. Dr. Farrell is a fellow or honorary fellow of several professional bodies, including the US National Academy of Engineering. He was inducted as 1998 San Diego Entrepreneur of the Year for Health Sciences, 2001 Australian Entrepreneur of the Year and 2005 US National Entrepreneur of the Year for Health Sciences. In 1998, Peter joined the Sleep Medicine Executive Council at Harvard Medical School, served as vice chairman from 2000 to 2010 and then as chairman from 2010 until 2013. He is on various academic advisory boards including UCSD's Jacobs School of Engineering, where he was named the 2012 Gordon Fellow, UCSD's Rady Business School and the MIT Dean of Engineering's Advisory Council. Peter holds a B.E. with honors in chemical engineering from the University of Sydney, an SM in chemical engineering from MIT, a PhD in bioengineering from the University of Washington, Seattle, and a DSc from UNSW for research which resulted in improved treatment for both hemodialysis and peritoneal dialysis patients.

Joseph Payne

Mr. Joseph E. Payne is President, Chief Executive Officer, Director of the Company. He serves on the board of directors of Arcturus Therapeutics Ltd. (formerly Alcobra Ltd.) since November 2017. Prior to joining Arcturus, Mr. Payne served as Senior Manager of Nitto Denko Corporation, a life sciences research company, from June 2009 until February 2013. Mr. Payne’s background includes over 20 years of drug discovery experience at Arcturus, Nitto Denko Corporation, Kalypsys Inc., Merck Research Labs, Bristol-Myers Squibb Co. and DuPont Pharmaceuticals Co. Mr. Payne received a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and an Executive Training Certificate from MIT Sloan School of Management.

Andrew Sassine

Mr. Andrew Heroux Sassine is Interim Chief Financial Officer, Director of the Company. Mr. Sassine also serves on the board of directors of Nasdaq listed Gemphire Therapeutics, Inc.(GEMP), an early-stage cardiovascular drug company formed by a licensing agreement with Pfizer Inc. He also is Chairman of the Board of privately held ComHear Inc., a digital audio software and device company. Mr. Sassine previously served on the board of Acorn Energy, Inc, CNS Response, Inc. and FluoroPharma Medical, Inc., (FMPI). Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including, most recently as Portfolio Manager. Between 2004 and 2011, he managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund. Mr. Sassine joined Fidelity as a high yield research analyst, covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Prior to joining Fidelity, he served as a vice president in the Acquisition Finance Group at Fleet National Bank. Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors since 2009 and served on the Board of Trustees at the Clarke Schools for Hearing and Speech between 2009 and 2014. Mr. Sassine earned a Bachelor of Arts degree at the University of Iowa in 1987 and an MBA from the Wharton School at the University of Pennsylvania in 1993.

Pad Chivukula

Dr. Pad Chivukula is Chief Operating Officer, Chief Scientific Officer of the Company. He has served on Arcturus’s Board since March 2013. Prior to Arcturus, from June 2008 until February 2013, Dr. Chivukula was employed by Nitto Denko Corporation, where his titles included Group Leader and Chief Scientist, and where he led the polymeric RNAi research department. Dr. Chivukula's background includes over 15 years of experience in drug delivery and therapeutic drug development at Nitto Denko Corporation and the University of Utah. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in lipid-mediated delivery systems and technology.

Kevin Skol

Mr. Kevin T. Skol is Senior Vice President of Business Development & Alliance Management of the Company. Kevin Skol has nearly 20 years of experience in the pharmaceutical industry, primarily in corporate development, alliance management, strategy and licensing roles. He previously worked at RNA target-based companies Ionis Pharmaceuticals and Digital Gene Technologies and at specialty pharmaceutical companies Elan Corporation and Valeant Pharmaceuticals. At Ionis he led business development and licensing efforts that resulted in major pharmaceutical partnerships with Astra Zeneca, Roche, Janssen, Novartis and Biogen. The combined transaction value of collaborative agreements and partnerships which he led throughout his career is estimated at over $2 billion. Mr. Skol graduated with a B.A. from Yale University and has an MBA from Harvard Business School.

K. Kummerfeld

Suezanne Parker

Ms. Suezanne Parker is Vice President - Translational Biology of the Company. Suezanne Parker, Ph.D., brings over 20 years of pharmaceutical industry experience in drug development from research/discovery through post-marketing. At Shire she led the nonclinical efforts for the marketing applications for Xiidra®, Vyvanse®, and Takhzyro®. Prior to Shire, Dr. Parker spent 13 years at Biogen Idec Pharmaceuticals where she was Director of Preclinical Safety, supporting marketed products to treat multiple sclerosis (Avonex®, Tysabri®, and Fampridine®) as well as developmental candidates from research through late stage development. She began her career in the industry at Vical Inc. where she led the preclinical efforts for some of the first human trials for plasmid DNA therapy. She has worked with several technologies (gene therapy, small molecules, biologics) and across multiple therapeutic areas (vaccines, infectious disease, neurology, immunology, oncology, ophthalmology and rare disease). Dr. Parker completed her postdoctoral studies at Scripps Clinic and Research Foundation, studying the viral pathogenesis of CNS diseases. She received a Ph.D. in Biochemistry and Molecular Biology from the University of California, Santa Barbara.

James Barlow

Mr. James Barlow is Director of the Company. He is a member of the Board of Directors of North American Health Care, Inc., a privately held company that provides contractual services to facilities specializing in post-acute care, subacute care, short and long-term rehabilitation, and skilled nursing in the United States. Mr. Barlow is a C-level financial executive with more than30 years of experience leading teams in the successful strategic achievement of financial and operational goals, and expertise in domestic and international operations (5 continents, 23 countries), financial planning, forecasting and reporting, restructurings, business development and integrations, treasury and investor relations. As an Executive Officer (Principal Accounting Officer) at Allergan, Inc. (NYSE:AGN), he oversaw financial due diligence, integration and structuring for more than 100 asset purchases, sales, business combinations and licensing transactions, the spin-off of Advanced Medical Optics, the $3.3 billion acquisition of Inamed and more than $4.5billion in other transactions. He ensured consistent application of all corporate policies and procedures and alignment with global reporting and corporate compliance requirements, made recommendations globally to improve financial operations and participated in robust financial planning/forecasting activities.

Magda Marquet

Dr. Magda Marquet is Director of the Company. Dr. Magda Marquet is the co-founder and co-CEO of Alma Life Sciences, an investment and consulting firm with a portfolio of over twenty companies in the areas of diagnostics, digital health and pharmaceuticals, Chairman and co-Founder of Althea, an Ajinomoto company, and Co-founder of AltheaDx, a precision medicine company. She has three decades of experience in the biotechnology industry in the US and Europe. Prior to starting Althea, Dr. Marquet held management positions at Vical Inc., Amylin Pharmaceuticals, Protein Polymer Technologies, Syntro Corporation and Transgene. She currently serves as a Board member for Sente, Independa and Portable Genomics. She is also co-Chairman of the Advisory Board of MD Revolution. Dr. Marquet was Chairman of BIOCOM (2013-2014) and is Chair of the Board of Visitors of the UCSD Moores Cancer Center. She serves as a Director of the Economic Development Corporation (EDC- Executive Committee) and of the Kyoto Symposium Organization. She is also a member of the UCSD Biological Sciences Dean Leadership Council and an advisor for the Chopra Foundation. Dr. Marquet holds a Ph.D in Biochemical Engineering from INSA/University of Toulouse, France. Dr. Marquet has received numerous awards throughout her career including the 2005 Regional Ernst&Young Entrepreneur of the Year Award in the Life Sciences category, the Athena Pinnacle Award and the Exemplary Service Award from the San Diego Business Journal. She is the first woman inducted in the Connect Entrepreneur Hall of Fame (2016) and the Director of the Year Award recipient (2016-Corporate Governance) from the Corporate Directors Forum. Joseph E. Payne, Director of the Board Joseph E. Payne, Director of the Board Joseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics Ltd. He serves on Arcturus’s Board since March 2013.